Twitter Facebook LinkedIn
Center for Global Research Data

Approved Research Proposals

The table provides details of approved research proposals that have signed Data Use Agreements.

Data Request IDLead InvestigatorInstitutionResearch Proposal Title
3244Vojtech HuserNational Library of Medicine/NIHIdentification of Research Common Data Elements in HIV/AIDS using data science methods
3246Dawn FarrellInstitute of Technology Tralee​Cochrane Review: Interventions for fatigue in inflammatory bowel disease
3270Mirjana Stanic BenicUniversity Hospital Centre Rijeka​The impact of biological interventions on health‐related quality of life in adults with Crohn's disease
3287Robert AlexanderTakedaIdentification of biomarkers associated with specific sleep variables
3288Marc-Antoine SparfelTours Hospital MIDRA: influence of demographic and environmental factors on anti-tumor necrosis factor efficacy in rheumatoid arthritis a systematic review and meta-analysis of randomized controlled trials
3320John FrewRockefeller UniversityAnalysis of Outcome Measures in Hidradenitis Suppurativa
3321Ewa OlechIQVIA Study of entry variables to optimize lupus trial design
3328Klaus GottliebEli Lilly USAMapping of components of the complete blood count and comprehensive metabolic profile to disease-specific clinical and endoscopy endpoints in phase 2 and 3 clinical trials of ulcerative colitis and Crohn’s disease
3361Gustav NilsonneKarolinska InstitutetDistribution of interleukin -6 in human plasma implications for statistical modelling and meta-analysis
3369 Michael Ward
NIH Predicting Treatment Response to Tumor Necrosis Factor Inhibitors in Patients with Ankylosing Spondylitis
3762Lin WangJohns Hopkins HospitalThe relative efficacy and safety of apalutamide, enzalutamide, abiraterone, and darolutamide for nonmetastatic castration-resistant prostate cancer
3876Changyu ShenBeth Israel Deaconess Medical CenterRisk and Benefit Stratification of Treatment Effects in Patients with Atrial Fibrillation
4036Akira KimataUniversity of TsukubaOptimal interruption time of dabigatran per OS to Ablation (O-A time) in patients with atrial fibrillation Integrated analysis of 2 randomized controlled clinical trials
4037Karl PeaceGeorgia Southern UniversityAssessment of Matching Methods for Causal Analysis
4039Claire DaienCHU lapeyronie The most appropriate conventional DMARD to combine with tofacitinib in Rheumatoid Arthritis post hoc analysis of ORAL sync study
4043Janneke van der WoudeErasmus Medical Center Effect of treatment on lipid profiles in patients with inflammatory bowel disease a systematic review and meta-analysis
4047Miriam Oron
Skintelligence ltd.Test the prospects of expending the Skintelligence algorithm for predicting response to treatment with Alefacept and Ustekinumab in psoriatic patients affected with type I diabetes
4048, 4329Shomron Ben-HorinSun Yatsen 1st affiliated HospitalEfficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease
4112Florian NaudetCHU RennesTolerability of duloxetine in the elderly and in adults: a systematic review and individual patient data meta-analysis of randomized controlled trials versus placebo
4113Lesley InkerTufts Medical CenterChronic Kidney Disease Epidemiology – Clinical Trials Consortium (CKD-EPI CT)
4115Amir MahabadiUniversity Hospital Essen, West German Heart and Vascular Center Impact of statin therapy on coronary artery calcification volume and density – A meta-analysis of randomized controlled trials
4116 Sharon StraussSt. Michael’s HospitalComparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia a systematic review and individual patient data network meta-analysis
4117John FrewRockefeller UniversityPredictors of Treatment Response, Adverse Events, Changes in Anaemia status and Assessment of Lesion Count Variability in Hidradenitis Suppurativa
4118J. David SpenceWestern UniversityOn-Treatment analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial
4120Merryn VoyseyUniversity of Oxford The immunogenicity and sero-efficacy of pneumococcal vaccines
4121Frederikus KlokLeiden University Medical CenterPerformance of the AF-adapted VTE-BLEED score for predicting major bleeding in patients with atrial fibrillation a post-hoc analysis of the ENGAGE-AF TIMI-48 Study
4275Lisa StampUniversity of OtagoSerum urate as a biomarker in gout Protocol for individual patient data analysis for OMERACT 2020
4278Jennifer QuintImperial College London Withdrawing inhaled corticosteroid (ICS) treatment in people with COPD a real world study
4316Martin OkunFort HealthCareGeospatial and Seasonal Variation in Psoriasis Severity Analysis of Placebo Response Data from Phase 3 placebo-controlled trials in moderate-severe psoriasis
4319Maria Alice FranzoiJules Bordet Institut
Clinical implications of body mass index and weight in metastatic breast cancer patients receiving abemaciclib. A combined individual patient level data sub-analysis of MONARCH 2 and MONARCH 3 trials
4326John MarkmanUniversity of Rochester Phenotypic Characterization of Chronic Neuropathic Pain Following Post-Traumatic and Post-Surgical Injury
4327Michael SzarekSUNY Downstate Medical CenterAnalysis of Total Events and Hospitalizations in the SPARCL Study
4330Laure GossecSorbonne UniversitéDomains of health important for Rheumatoid Arthritis patients can be assessed separately: Reliability and Responsiveness of the Rheumatoid Arthritis Impact of Disease Score - 7 items (RAID.7i)
4352Stefano BarcoUniversity Medical Center MainzDifferential effects of long-term treatment with warfarin vs. edoxaban on blood count parameters. A parallel posthoc analysis of the Hokusai VTE and Engage AF-TIMI-48 trials
4540Chris GaleUniversity of LeedsEfficacy and safety of edoxaban versus warfarin in patients with atrial fibrillation and frailty insights from the ENGAGE AF-TIMI 48 trial
4541C Elizabeth CaldonGarvan Institute of Medical ResearchTherapeutic targeting of dual CDK4/6 inhibitor and endocrine resistant breast cancer
4913Susan HalabiDuke University Surrogate Endpoints of Overall Survival in Non-Metastatic Renal Clear Cell Carcinoma
4915Rachel TomkoMedical University of South CarolinaPredicting Individuals' Probability of Response to Smoking Cessation Pharmacotherapy
4918Nina HilkensRadboudmc NijmegenAssociation between blood pressure, blood pressure variability and the risk of post-stroke dementia
4919Hendrik Jan GuchelaarLeiden University Medical Center (LUMC)Effect of digoxin on survival outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors
4920Gustavo TureckiDouglas Mental Health University InstitutePredicting Treatment Efficacy in Individuals with Major Depression -- Deep Neural Networks for Physiological Patient Parameters
4921Tim BrümmendorfUniversity Hospital Aachen Entropy – based Biomarkers for individualized response on Bosutinib treatment in chronic phase CML
4922, 3274Diane van der WoudeLeiden University Medical Center​Effect of rheumatoid factor and anticitrullinated peptide antibody on the efficacy of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
4926Eva-Maria GamperMedical University InnsbruckComparison of the EORTC QLU-C10D with generic utility instruments and development of a comprehensive manual for its use
4931Siddharth SinghUniversity of California, San DiegoEarly changes in inflammatory biomarkers and long-term outcomes in patients with IBD: A pooled post-hoc analyses of clinical trials
4933Hongxia WangShanghai Jiao Tong University School of Medicine Novel predictive biomarker for therapeutic sensitivity of CKD4/6 inhibitor in breast cancer patients
4949, 3190Vivek RudrapatnaUniversity of California San FranciscoEfficacy of Crohn’s Disease Treatment Stratified by Disease Phenotype
4950John “Devin” PeipertNorthwestern University Justification of PROMIS (FACIT) Fatigue Short Form 10a scale for FDA Drug Development ToolQualification in Rheumatoid Arthritis
5073Philip RobinsonUniversity of QueenslandAssessment of treatment outcome using ASAS40 with etanercept in non-radiographic axSpA by baseline CRP - a re-analysis of trial data
5074Sebastian ZundlerUniversity Hospital ErlangenEvaluation of the relationship between vedolizumab peripheral blood serum level at week 6 and binary clinical outcomes at week 10/14 - a meta-analysis
5079Maureen DubreuilBoston UniversityClinical and MRI predictors of Clinical Response in Axial Spondyloarthritis
5080Joel SkaistisBeaumont Health Benefit of Anticoagulation in Cryptogenic Stroke According to Biomarker Level
5086Junko TakeshitaUniversity of PennsylvaniaA Systematic Review to Describe the Demographic Diversity of Dermatologic Clinical Trial Participants for Common Dermatologic Diseases
5095Mathilde NijkeuterUniversity Medical Center UtrechtAssessing bleeding risk in patients with cancer-associated thrombosis
5096Joo Sang LeeSamsung Medical Center, South KoreaHarnessing genetic interactions to advance precision cancer medicine
5098Christopher BaethgeUniversity of Cologne Medical School Dose-response relationships in antidepressant pharmacotherapy of depressive disorders with (S)SNRI: a systematic review and meta-analysis
5099Jorge HernandoVall d ́Hebron University Hospital Impact of gender on multikinase inhibitors (MKIs) toxicity in patients (pts) with advanced pancreatic and gastrointestinal neuroendocrine tumors (NETs)
5163Susan BatesColumbia University Medical CenterAssessing the tumor growth and decay rates in patients with pancreatic cancer treated with Gemcitabine/Abraxane: Comparing real world data with clinical trial data
5165Byeongzu GhangJeju National University HospitalReanalysis of CARES study to investigate the incidence of cardiovascular events and death after initiation and discontinuation of allopurinol and febuxostat
5166Thomas MetkusJohns Hopkins University School of Medicine Severe sepsis in the cardiac intensive care unit: management strategies and outcomes
5207Gisli JenkinsUniversity of NottinghamA systematic review and individual patient data meta-analysis of physiological biomarkers in idiopathic pulmonary fibrosis
5276Yan LuoKyoto UniversityPredicting the Treatment Response of Certolizumab for Individual Patients with Rheumatoid Arthritis: An Individual Participant Data Meta-Analysis
5289, 5323Ashley HopkinsFlinders UniversityPredictors of therapeutic and adverse effects of medicines used in the treatment of breast cancer
5290Ashley HopkinsFlinders UniversityPredictors of therapeutic and adverse effects of medicines used in the treatment of gastrointestinal cancers
5291Sarah NevittUniversity of LiverpoolAntiepileptic drug monotherapy for epilepsy: an updated Cochrane review and individual participant data network meta-analysis
5292Désirée van der HeijdeLeiden University Medical CenterMeasurement properties of the instruments used in the outcome assessment of axial spondyloarthritis
5294Daniel CaldeiraUniversity of Lisbon/CCUL The clinical impact of dabigratran in patients with non-valvular atrial fibrillation who had a fall or head injury: a retrospective analysis of RE-LY
5324. 5325Daniel GoldenholzBeth Israel Deaconess Medical Center Retrospective analysis of placebo arm data in clinical epilepsy trials
5330Laura BonnettUniversity of LiverpoolModelling seizure rates rather than time to an event within clinical trials of antiepileptic drugs
5352Elena MyasoedovaMayo ClinicIndividualized Prediction of Treatment Response to Methotrexate in Patients with Rheumatoid Arthritis: A Machine Learning Approach
5435Matthew GilbertUniversity of VermontEffect of Albiglutide on Cardiovascular Outcomes in Older Adults with Type 2 Diabetes: a Post Hoc Analysis of a Randomized Controlled Trial
5456Jane LarkindaleCritical Path Institute Validation of a Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular Dystrophy
5484Stefan LeuchtTechnical University of MunichIndividual-patient-data (IPD) meta-analysis of the efficacy of clozapine versus second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia
5485Günter HöglingerHanover Medical SchoolPrediction model for individual disease progression in patients with progressive supranuclear palsy
5567Neeraj NarulaMcMaster UniversityImpact of Ulcer Size and Extent of Inflammation On Ability To Achieve Endoscopic Healing In Crohn’s Disease: An EXTEND Post-Hoc Analysis
5812Yougen WuThe Fifth People's Hospital of Shanghai, Fudan UniversityDevelopment and validation of nomograms for predicting efficacy and toxicity in cancer patients treated with immune checkpoint inhibitors
5813Phillip GarfinSeattle Genetics Inc.Effectiveness of cytotoxic chemotherapy for the treatment metastatic breast cancer subtypes
5852Marliese AlexanderPeter MacCallum Cancer Centre Infective outcomes in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: an individual patient data meta-analysis
5869Alexandra FreemanUniversity of CambridgeMeta-analysis of the adverse effects of trastuzumab in women with breast cancer
5871Nobuhisa KanaharaChiba University Center for Forensic Mental Health Determination of dopamine supersensitivity psychosis in randomized controlled studies of long-acting injectable vs. oral agents of the same atypical antipsychotic in schizophrenia subjects
5872Yaw NyameUniversity of Washington Medical CenterRepresentation of Low-Grade Prostate Cancer in Metastatic Prostate Cancer Trials
5880Benjamin SchneiderIowa State UniversityOptimal Scheduling of First-Line Therapeutics in Non-Small Cell Lung Cancer
5894Takashi SozuTokyo University of ScienceMatrix Decomposition in Meta-Analysis for Extraction of Adverse Event Pattern and Patient-Level Safety Profile
5897John PeipertNorthwestern UniversityJustification of PROMIS (FACIT) Fatigue Short Form 10a scale for FDA Drug Development Tool Qualification in Rheumatoid Arthritis
5901Junhao HuChinese Academy of Science Vessel pericytes NO-sGC signaling in COVID-19
5902Thrasyvoulos TzellosNorland University HospitalDevelopment and validation of a IHS4 dichotomous outcome for assessing anti-inflammatory treatment efficacy for the treatment of hidradenitis suppurativa
5904Saskia MiddeldorpAmsterdam UMCHokusai post VTE study: long-term outcome after heparin plus edoxaban versus heparin plus vitamin K antagonists for acute deep vein thrombosis and pulmonary embolism
5925Min Hwan KimYonsei University College of MedicineAnalysis of neutrophil to lymphocyte ratio (NLR) in ER+ breast cancer patients to predict palbociclib clinical response
5930Youssef ZeidanAmerican University of Beirut Medical CenterEvaluation of Radiotherapy Boost in Women with HER-2 positive Breast Cancer
5931Youssef ZeidanAmerican University of Beirut Medical CenterEvaluation of Radiotherapy in Triple Negative Breast Cancer: Analysis of the BEATRICE trial
5932Youssef ZeidanAmerican University of Beirut Medical CenterEvaluation of Radiotherapy after Complete Response to Neoadjuvant Chemotherapy in HER-2 Positive Breast Cancer Patients
5933, 5208Ahmad AbuhelwaUniversity of South AustraliaPredictors of exposure, therapeutic and adverse effects of certolizumab pegol and baricitinib used in the treatment of rheumatoid arthritis
5936Zhi XiaoXiangya Hospital, Central-South UniversityRoles of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy
5944Pietro SpitaliLeiden University Medical CenterPrediction of disease progression in Duchenne muscular dystrophy
5945Neeraj NarulaMcMaster UniversityPredictors of Mucosal Healing in Ulcerative Colitis: A Post-hoc Analysis of VARSITY
5948Georgia SalantiUniversity of BernMaking real world predictions for clinical outcomes in Relapsing-Remitting Multiple Sclerosis
5950Shirley WangBrigham and Women's HospitalUnderstanding effectiveness of new drugs in older adults shortly after market entry
5951, 4543Mathilde NijkeuterUMC UtrechtIndividualized prediction of recurrence risk reduction and risk of bleeding with extended anticoagulation in patients with venous thromboembolism
5959John DennisUniversity of Exeter Medical SchoolStratification of SGLT2 inhibitor glucose lowering therapy in Type 2 diabetes
5960Matt LinnikEli Lilly & Co.Covid-19 Pulmonary Gene Expression Analysis
5974Robert SchoeversUniversity of GroningenPrescriber effects on outcome of psychopharmacological treatment of Major Depressive Disorder (MDD)
5982Matthew BakerStanford UniversityInvestigating the effects of rituximab on specific cell subsets and cytokine levels in systemic lupus erythematosus patients and constructing a prediction model of treatment response
5984David BakerQueen Mary University of LondonExploring possibilities to improve the riskbenefit balance through anlaysis of the ocrelizumab phase II extension study
5985, 5327Jose Antonio Pereira da SilvaUniversidade de Coimbra, PortugalLong-term predictive value of patient global assessment regarding radiographic damage and physical function in patients with Rheumatoid Arthritis: individual patient data meta-analysis
5988Elad SharonNational Cancer InstituteThe Role of Targeted Agents and Their Effects on Lymphocytes and Patient Outcomes
5989Jane LarkindaleCritical Path InstituteSharing of Progressive Supranuclear Palsy (PSP) data with the Rare Disease Cures Accelerator - Data and Analytics Platform for Analysis of Outcome Measures and Other Purposes
6004Lily LimUniversity of ManitobaIdentifying Trajectories of Disease Activity States in Juvenile Idiopathic Arthritis (JIA) Early After Treatment: Shortening Time to Decision to Change Treatment
6006Nicholas WhiteMahidol UniversityA Multiple-Dose Study to Assess the Effects of Azithromycin plus Chloroquine on Electrocardiograms in Healthy Subjects - COVID-19
6007Judith GoldsteinJohns Hopkins School of MedicineNational Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) Calibrations for Low Vision Patients with age-related macular degeneration (AMD)
6041Neeraj NarulaHamilton Health SciencesHistologic Predictors of Endoscopic Healing in Crohn's Disease
6117, 5895Ashley HopkinsFlinders University Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers